Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Dec;33(12):2063–2068. doi: 10.1128/aac.33.12.2063

Oral and parenteral therapy with saperconazole (R 66905) of invasive aspergillosis in normal and immunocompromised animals.

J Van Cutsem 1, F Van Gerven 1, P A Janssen 1
PMCID: PMC172822  PMID: 2619273

Abstract

Saperconazole (R 66905) is a broad-spectrum antifungal triazole with potent in vitro activity against Aspergillus spp. A total of 279 strains were tested in brain heart infusion broth. Development of the Aspergillus spp. was completely inhibited at 0.1 and 1 microgram of saperconazole per ml for 80.3 and 99.6% of the strains, respectively. Normal and immunocompromised guinea pigs were infected intravenously with Aspergillus fumigatus and treated orally, intravenously, or intraperitoneally with saperconazole or intraperitoneally with amphotericin B. Leukopenia, neutropenia, lymphocytosis, and monocytosis were obtained with mechlorethamine hydrochloride; leukopenia, neutrophilia, and lymphopenia were obtained with cyclophosphamide. Saperconazole was dissolved for oral treatment in polyethylene glycol and for parenteral treatment in cyclodextrins. Amphotericin B was given parenterally as Fungizone (E.R. Squibb & Sons). Treatment was given once daily for 14 days. An early starting treatment was efficacious, but the activity of saperconazole was maintained even when the onset of the treatment was delayed to the moribund state. The activity of saperconazole was not altered in immunocompromised animals. Saperconazole was clearly superior to amphotericin B and free of side effects. The oral and parenteral formulations of saperconazole were equipotent. The systemic activity of saperconazole in guinea pigs was confirmed in invasive aspergillosis in pigeons.

Full text

PDF
2065

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aisner J., Murillo J., Schimpff S. C., Steere A. C. Invasive aspergillosis in acute leukemia: correlation with nose cultures and antibiotic use. Ann Intern Med. 1979 Jan;90(1):4–9. doi: 10.7326/0003-4819-90-1-4. [DOI] [PubMed] [Google Scholar]
  2. Cauwenbergh G., Van Cutsem J. Role of animal and human pharmacology in antifungal drug design. Ann N Y Acad Sci. 1988;544:264–269. doi: 10.1111/j.1749-6632.1988.tb40412.x. [DOI] [PubMed] [Google Scholar]
  3. Espinel-Ingroff A., Shadomy S., Gebhart R. J. In vitro studies with R 51,211 (itraconazole). Antimicrob Agents Chemother. 1984 Jul;26(1):5–9. doi: 10.1128/aac.26.1.5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Graybill J. R., Ahrens J. Itraconazole treatment of murine aspergillosis. Sabouraudia. 1985 Jun;23(3):219–223. doi: 10.1080/00362178585380321. [DOI] [PubMed] [Google Scholar]
  5. Heeres J., Backx L. J., Van Cutsem J. Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones. J Med Chem. 1984 Jul;27(7):894–900. doi: 10.1021/jm00373a015. [DOI] [PubMed] [Google Scholar]
  6. Odds F. C., Webster C. E., Abbott A. B. Antifungal relative inhibition factors: BAY l-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents. J Antimicrob Chemother. 1984 Aug;14(2):105–114. doi: 10.1093/jac/14.2.105. [DOI] [PubMed] [Google Scholar]
  7. Pennington J. E. Aspergillus pneumonia in hematologic malignancy. Improvements in diagnosis and therapy. Arch Intern Med. 1977 Jun;137(6):769–771. [PubMed] [Google Scholar]
  8. Saag M. S., Dismukes W. E. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother. 1988 Jan;32(1):1–8. doi: 10.1128/aac.32.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Van Cutsem J. Antifungal activity of enilconazole on experimental Aspergillosis in chickens. Avian Dis. 1983 Jan-Mar;27(1):36–42. [PubMed] [Google Scholar]
  10. Van Cutsem J., Van Gerven F., Janssen P. A. Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S15–S32. doi: 10.1093/clinids/9.supplement_1.s15. [DOI] [PubMed] [Google Scholar]
  11. Van Cutsem J., Van Gerven F., Janssen P. A. In vitro activity of enilconazole against Aspergillus spp. and its fungicidal efficacy in a smoke generator against Aspergillus fumigatus. Mycoses. 1988 Mar;31(3):143–147. [PubMed] [Google Scholar]
  12. Van Cutsem J., Van Gerven F., Van de Ven M. A., Borgers M., Janssen P. A. Itraconazole, a new triazole that is orally active in aspergillosis. Antimicrob Agents Chemother. 1984 Oct;26(4):527–534. doi: 10.1128/aac.26.4.527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Young R. C., Bennett J. E., Vogel C. L., Carbone P. P., DeVita V. T. Aspergillosis. The spectrum of the disease in 98 patients. Medicine (Baltimore) 1970 Mar;49(2):147–173. doi: 10.1097/00005792-197003000-00002. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES